Philippines

BMI View: The government of the Philippines' increasing efforts in healthcare provision are positive for pharmaceutical and medical devices sales, however, more has to be done in order... 2012-01-18

BMI View: While the approval of Roche 's Avastin (bevacizumab) as a first-line treatment for ovarian cancer in the Philippines is a positive decision that will moderate the burden... 2011-10-28

BMI View: The medical device market of the Philippines represents a moderate opportunity for foreign manufacturers. The key drivers of growth are government investments in healthcare... 2011-05-12

BMI Core View: Drugmakers will increasingly use differential pricing in emerging markets. Pharmaceutical companies generally price their patented medicines at the maximum the market... 2011-01-26

Developed state underperformance remains a recurring theme within our Industry analysis. We remain concerned about US labour market weakness and its impact, particularly on consumer... 2010-09-28

Asia Pacific's respect for intellectual property rights with regard to medicine has improved marginally over the past 12 months, according to the Pharmaceutical Research and Manufacturers... 2010-03-09

BMI is maintaining its forecast for the Philippines pharmaceutical market despite another round of medicine price cuts. The Department of Health expects the lower prices of 97 preparations... 2010-03-02

In a bid to boost drug sales in certain emerging markets, multinational drugmaker Sanofi-Aventis has cut the prices of some of its drugs by as much as 50% in the Philippines and Indonesia.... 2010-01-14

Bureaucracy and a lack of funding are hampering the implementation of the Universally Accessible Cheaper and Quality Medicines Act in the Philippines. Only 21 pharmaceuticals have... 2009-12-23

BMI has upgraded the Philippines' score for 'Approval process' on our Pharmaceuticals & Healthcare Business Environment Rankings from four to five, following the formation of... 2009-08-27